465 results on '"Sullivan, Daniel M."'
Search Results
2. Spending and Job-Finding Impacts of Expanded Unemployment Benefits: Evidence from Administrative Micro Data.
3. Data from Selective Nuclear Export Inhibitor KPT-330 Enhances the Antitumor Activity of Gemcitabine in Human Pancreatic Cancer
4. Supplementary Figure S1 from Selective Nuclear Export Inhibitor KPT-330 Enhances the Antitumor Activity of Gemcitabine in Human Pancreatic Cancer
5. Supplementary legend from Selective Nuclear Export Inhibitor KPT-330 Enhances the Antitumor Activity of Gemcitabine in Human Pancreatic Cancer
6. A Large PEST-Like Sequence Directs the Ubiquitination, Endocytosis, and Vacuolar Degradation of the Yeast a-Factor Receptor
7. Data from Phase I Clinical Trial of Selinexor in Combination with Daunorubicin and Cytarabine in Previously Untreated Poor-Risk Acute Myeloid Leukemia
8. Supplementary Expression Data from Randomized Trial of Oral Cyclophosphamide and Veliparib in High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers, or BRCA-Mutant Ovarian Cancer
9. Figure S3 from Randomized Trial of Oral Cyclophosphamide and Veliparib in High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers, or BRCA-Mutant Ovarian Cancer
10. Supplementary Methods, Tables S1 and S2, Figure Legend from Randomized Trial of Oral Cyclophosphamide and Veliparib in High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers, or BRCA-Mutant Ovarian Cancer
11. Sup Figure 3 from Interrogating Two Schedules of the AKT Inhibitor MK-2206 in Patients with Advanced Solid Tumors Incorporating Novel Pharmacodynamic and Functional Imaging Biomarkers
12. Sup Figure 4 from Interrogating Two Schedules of the AKT Inhibitor MK-2206 in Patients with Advanced Solid Tumors Incorporating Novel Pharmacodynamic and Functional Imaging Biomarkers
13. Sup Figure 1 from Interrogating Two Schedules of the AKT Inhibitor MK-2206 in Patients with Advanced Solid Tumors Incorporating Novel Pharmacodynamic and Functional Imaging Biomarkers
14. Supplementary Data from Phase I Clinical Trial of Selinexor in Combination with Daunorubicin and Cytarabine in Previously Untreated Poor-Risk Acute Myeloid Leukemia
15. Supplementary Data from Melphalan and Exportin 1 Inhibitors Exert Synergistic Antitumor Effects in Preclinical Models of Human Multiple Myeloma
16. Supplementary Data from Potentiation of a Topoisomerase I Inhibitor, Karenitecin, by the Histone Deacetylase Inhibitor Valproic Acid in Melanoma: Translational and Phase I/II Clinical Trial
17. Data from Randomized Trial of Oral Cyclophosphamide and Veliparib in High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers, or BRCA-Mutant Ovarian Cancer
18. Data from Melphalan and Exportin 1 Inhibitors Exert Synergistic Antitumor Effects in Preclinical Models of Human Multiple Myeloma
19. Sup Figure 2 from Interrogating Two Schedules of the AKT Inhibitor MK-2206 in Patients with Advanced Solid Tumors Incorporating Novel Pharmacodynamic and Functional Imaging Biomarkers
20. Supplementary Data from Phase I Trial of Bortezomib (PS-341; NSC 681239) and Alvocidib (Flavopiridol; NSC 649890) in Patients with Recurrent or Refractory B-Cell Neoplasms
21. Supplementary Methods and Table 1 from Phase I Study of Topotecan, Ifosfamide, and Etoposide (TIME) with Autologous Stem Cell Transplant in Refractory Cancer: Pharmacokinetic and Pharmacodynamic Correlates
22. Supplementary Data from Interrogating Two Schedules of the AKT Inhibitor MK-2206 in Patients with Advanced Solid Tumors Incorporating Novel Pharmacodynamic and Functional Imaging Biomarkers
23. Supplementary Data from Novel 5′ Untranslated Region Variants of BCRP mRNA Are Differentially Expressed in Drug-Selected Cancer Cells and in Normal Human Tissues: Implications for Drug Resistance, Tissue-Specific Expression, and Alternative Promoter Usage
24. Supplementary Table S1 from Novel 5′ Untranslated Region Variants of BCRP mRNA Are Differentially Expressed in Drug-Selected Cancer Cells and in Normal Human Tissues: Implications for Drug Resistance, Tissue-Specific Expression, and Alternative Promoter Usage
25. Data from Novel 5′ Untranslated Region Variants of BCRP mRNA Are Differentially Expressed in Drug-Selected Cancer Cells and in Normal Human Tissues: Implications for Drug Resistance, Tissue-Specific Expression, and Alternative Promoter Usage
26. Student Motivations, Perceptions and Opinions of Participating in Student Evaluation of Teaching Surveys: A Scoping Review
27. Air Quality Impacts of Shale Gas Development in Pennsylvania
28. Randomized multicenter phase 2 study of pomalidomide, cyclophosphamide, and dexamethasone in relapsed refractory myeloma
29. Lawyers Steer Clients Toward Lucrative Filings: Evidence from Consumer Bankruptcies
30. Sequence of novel agents in multiple myeloma: An instrumental variable analysis
31. Spending and Job Search Impacts of Expanded Unemployment Benefits: Evidence from Administrative Micro Data
32. Reactive Oxygen Species in Proliferative Signaling
33. Maximally Tolerated Busulfan Systemic Exposure in Combination with Fludarabine as Conditioning before Allogeneic Hematopoietic Cell Transplantation
34. Lessons Learned from the Pandemic Unemployment Assistance Program during COVID-19
35. Spending and Job-Finding Impacts of Expanded Unemployment Benefits: Evidence from Administrative Micro Data.
36. Resistance to inhibitors of DNA topoisomerases
37. Functional Expression and Photoaffinity Labeling of a Cloned P 2U Purinergic Receptor
38. Gamma-secretase inhibitor enhances the cytotoxic effect of bortezomib in multiple myeloma
39. Phase I pharmacokinetic and pharmacodynamic study of triciribine phosphate monohydrate, a small-molecule inhibitor of AKT phosphorylation, in adult subjects with solid tumors containing activated AKT
40. Inhibition of Notch signaling induces apoptosis of myeloma cells and enhances sensitivity to chemotherapy
41. Phase II study of pegylated liposomal doxorubicin, low-dose dexamethasone, and lenalidomide in patients with newly diagnosed multiple myeloma
42. Signal Transduction Proteins in Tumors From Puerto Rican and Caucasian Gastric Adenocarcinoma Patients: Expression Differences With Potential for Specific Targeted Therapies
43. When unemployment insurance benefits are rolled back: Impacts on job finding and the recipients of the Pandemic Unemployment Assistance Program
44. The Online Platform Economy Through the Pandemic
45. FDG-PET Lymphoma Demonstration Project Invitational Workshop
46. The absolute bioavailability of oral vinorelbine in patients with solid tumors
47. Measurement of multisite oxidation kinetics reveals an active site conformational change in Spo0F as a result of protein oxidation
48. Melphalan and Exportin 1 Inhibitors Exert Synergistic Antitumor Effects in Preclinical Models of Human Multiple Myeloma
49. Implementation of Timeline Reforms Speeds Initiation of National Cancer Institute–Sponsored Trials
50. The creation of an integrated health-information platform: building the framework to support personalized medicine
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.